Sequella, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 1997-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.sequella.com
Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2013-08-19
- Lead Sponsor
- Sequella, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT01585636
- Locations
- 🇺🇸
Quintiles Phaes 1 Clinical Study Unit, Lenexa, Kansas, United States
Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Sequella, Inc.
- Registration Number
- NCT01252108
PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Sequella, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT01225640
- Locations
- 🇿🇦
Pfizer Investigational Site, Cape Town, South Africa
Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Sequella, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT00990990
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2013-08-27
- Lead Sponsor
- Sequella, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT00871949
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
© Copyright 2024. All Rights Reserved by MedPath